Skip to main content
Clinical Trials/NCT06231355
NCT06231355
Completed
Phase 4

Efficacy of Liposomal Bupivacaine Versus Conventional Bupivacaine for Pain Control in Patients Undergoing Laparoscopic Radical Nephrectomy: A Pilot Randomized Trial

Peking University First Hospital1 site in 1 country61 target enrollmentFebruary 21, 2024

Overview

Phase
Phase 4
Intervention
Performing paravertebral nerve block with lipo-bupivacaine
Conditions
Local Anesthetics
Sponsor
Peking University First Hospital
Enrollment
61
Locations
1
Primary Endpoint
A composite index of pain intensity and opioid consumption (PIOC) between 12 and 72 hours after surgery
Status
Completed
Last Updated
9 months ago

Overview

Brief Summary

The goal of this pilot study is to test the hypothesis that liposomal bupivacaine extends the duration of paravertebral block in patients undergoing radical nephrectomy, achieving improved analgesia compared to conventional bupivacaine. The main questions it aims to answer are:

  • Area under curve of numeric rating scale of pain from 12 to 72 h after surgery.
  • Cumulative opioid consumption during the period of 12 to 72 h after surgery.

Detailed Description

Random numbers will be generated by an independent biostatistician in a 1:1 ratio, sealed in sequentially numbered opaque envelopes, and stored by a study coordinator. Only anesthesiologists who perform paravertebral block know group allocation but are not involved in other parts of the trial. Patients, other health-care team members, and investigators for data collection and outcome assessment are masked from group assignments. Paravertebral block will be performed with either liposomal bupivacaine or plain bupivacaine. The efficacy of nerve block will be assessed every 5 minutes after local anesthetic injection. We will evaluate pain severity, opioid consumption, and occurrence of adverse events at the following timepoints, i.e., end of surgery, 30 minutes after surgery, and 2, 6, 12, 24, 36, 48, 60, and 72 hours after surgery. Additionally, occurrence of complications, quality of recovery, and subjective sleep quality will be assessed during hospital stay after surgery.

Registry
clinicaltrials.gov
Start Date
February 21, 2024
End Date
October 14, 2024
Last Updated
9 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Dong-Xin Wang

Professor

Peking University First Hospital

Eligibility Criteria

Inclusion Criteria

  • Age between 18 and 70 years old.
  • Scheduled for laparoscopic-assisted unilateral radical nephrectomy.
  • Agree to undergo regional nerve blockade and receive patient-controlled intravenous analgesia after surgery.

Exclusion Criteria

  • Renal cancer with venous thrombus of grade II or higher, or cases that may convert to open surgery.
  • Body mass index ≥30 kg/m² or ≤15 kg/m².
  • Severe renal dysfunction (serum creatinine \>442 μmol/L or requiring renal replacement therapy), severe liver dysfunction (Child-Pugh class C), or American Society of Anesthesiologists class ≥IV.
  • Contraindications for deep nerve block, including severe spinal deformity or history of spinal surgery, severe coagulation abnormalities (international normalized ratio \>1.7, activated partial thromboplastin time \>4 seconds above normal, platelet count \<80×10⁹/L), trauma or infection at the planned puncture site, or severe lumbar back pain.
  • Chronic opioid dependence and long-term use of various analgesics for more than 3 months.
  • Preoperative inability to communicate due to severe dementia, language barriers, or end-stage diseases.
  • Preoperative concomitant central nervous system and/or peripheral nervous system diseases.
  • Planned endotracheal intubation and admission to the intensive care unit after surgery.
  • Known allergy to local anesthetics.
  • Other conditions that are deemed unsuitable for trial participation by the attending surgeons or investigators.

Arms & Interventions

Lipo-bupivacaine

Paravertebral block is performed with liposomal bupivacaine.

Intervention: Performing paravertebral nerve block with lipo-bupivacaine

Bupivacaine

Paravertebral block is performed with bupivacaine.

Intervention: Performing paravertebral nerve block with bupivacaine

Outcomes

Primary Outcomes

A composite index of pain intensity and opioid consumption (PIOC) between 12 and 72 hours after surgery

Time Frame: Between 12 and 72 hours afer surgery

The composite index of pain intensity and opioid consumption (PIOC) will be calculated using the area under curve (AUC) of pain intensity and cumulative opioid consumption between 12 and 72 hours in the postoperative period.

Secondary Outcomes

  • Time to onset after paravertebral block(From end of nerve block to initiation of surgery.)
  • Time to maximal block after paravertebral block(From end of nerve block to initiation of surgery.)
  • Paravertebral block-related adverse events.(From end of nerve block to initiation of surgery.)
  • Extent of paravertebral block(From end of nerve block to 72 hours after surgery.)
  • Pain intensity within 72 hours after surgery(Up to 72 hours after surgery)
  • A composite index of pain intensity and opioid consumption (PIOC) within 72 hours after surgery.(Up to 72 hours after surgery)
  • Cumulative opioid consumption within 72 hours after surgery.(Up to 72 hours after surgery)

Study Sites (1)

Loading locations...

Similar Trials